| Literature DB >> 31407088 |
Sissel Nygaard1,2, Anders Haugom Christensen1,2, Katrine Rolid2,3, Kari Nytrøen2,3, Lars Gullestad2,3,4,5, Arnt Fiane6, Erik Thaulow1, Gaute Døhlen1, Kristin Godang7, J Philip Saul8, Vegard Bruun Bratholm Wyller9,10.
Abstract
PURPOSE: Heart transplantation causes denervation of the donor heart, but the consequences for cardiovascular homeostasis remain to be fully understood. The present study investigated cardiovascular autonomic control at supine rest, during orthostatic challenge and during isometric exercise in heart transplant recipients (HTxR).Entities:
Keywords: Autonomic cardiovascular control; Catecholamines; Denervation; Heart transplantation
Mesh:
Substances:
Year: 2019 PMID: 31407088 PMCID: PMC6763412 DOI: 10.1007/s00421-019-04207-5
Source DB: PubMed Journal: Eur J Appl Physiol ISSN: 1439-6319 Impact factor: 3.078
Criteria for inclusion and exclusion in AccHeart
| Inclusion criteria | Exclusion criteria | |
|---|---|---|
| Heart transplant recipients (HTxR) | Completed heart transplantation during the last 7–12 weeks Age > 16 years and < 70 years | Peri- or postoperative complications causing permanent dysfunction of the allograft (such as hyperacute rejection episodes, severe myocardial ischemia, etc.) Other chronic medical conditions, such as: Diabetes with HbA1C > 7.5% (mean value during 6 months prior to HTx) and/or manifest diabetic complications Renal failure with plasma creatinine > 200 µmol/l ECG abnormalities (scattered ectopic beats and minor conduction problems are allowed) Medical instability, non-compliance, multiorgan recipients, active infection or permanently bed-ridden patients |
| Healthy controls | Age and sex matching the patients | Other chronic diseases (such as diabetes mellitus) Permanent use of pharmaceuticals (including hormone drugs) Pregnancy |
Fig. 1Flowchart of HTxR inclusion in AccHEART
Characteristics of eligible heart transplant recipients during the study perioda, included vs. not included
| Included in AccHEART | Not included in AccHEART | ||
|---|---|---|---|
| Number | 50 | 20 | n.a. |
| Sex—no. (%) | |||
| Male | 35 (70) | 13 (65) | 0.684 |
| Female | 15 (30) | 7 (35) | |
| Ethnicity—no. (%) | |||
| Norwegian | 46 (92) | 17 (85) | 0.378 |
| Not Norwegian | 4 (8) | 3 (15) | |
| Age—years, mean (SD) | 48.2 (13.0) | 47.9 (13.4) | 0.924 |
| Heart failure prior to HTx—years, mean (SD) | 5.8 (5.5) | 7.1 (4.5) | 0.364 |
| Waiting list for HTx—months, mean (SD) | 3.1 (3.4) | 4.1 (3.9) | 0.305 |
| Causes of heart failure—no. (%) | |||
| Ischemic heart disease | 13 (26) | 7 (35) | 0.495 |
| Dilated cardiomyopathy | 23 (46) | 9 (45) | |
| Other | 14 (28) | 4 (20) | |
| Donor age—years, mean (SD) | 36.4 (13.4) | 42.4 (16.6) | 0.120 |
| Graft ischemic time—min, mean (SD) | 172 (80) | 145 (85) | 0.229 |
SD standard deviation, HTx heart transplant
aFrom January 2013 until December 2015. All HTx recipients at the Oslo University Hospital (the only transplant center in Norway) were screened for eligibility in AccHEART
bBased upon Chi square test, Fisher’s exact test or Student t test, as appropriate
Background characteristics of study participants
| HTx recipients | Healthy controls | ||
|---|---|---|---|
| Number | 50 | 50 | n.a. |
| Sex—no. (%) | |||
| Male | 35 (70) | 35 (70) | 1.000 |
| Female | 15 (30) | 15 (30) | |
| Ethnicity—no. (%) | |||
| Norwegian | 46 (92) | 48 (96) | 0.678 |
| Not Norwegian | 4 (8) | 2 (4) | |
| Age—years, mean (SD) | 48.2 (13.0) | 47.8 (12.4) | 0.861 |
| Body mass index—kg/m2, mean (SD) | 24.8 (3.8) | 25.2 (3.0) | 0.586 |
| Glomerular filtration rate, estimated—ml/min/1.73 m2, mean (SD) | 55.8 (16.6) | 92.2 (19.0) |
|
| HbA1c—%, mean (SD) | 5.7 (0.7) | 5.2 (0.3) |
|
| Steps per day—number, mean (SD) | 5409 (2345) | 8577 (3158) |
|
| Rejection episodes—no. (%) | n.a. | n.a. | |
| No rejection | 31.00 (62) | ||
| Grade 1 | 11.00 (22) | ||
| Grade 2 or more | 8.00 (16) | ||
Numbers in bold indicate a p value < 0.05
SD standard deviation, HTx heart transplant
aBased upon Chi square test, Fisher’s exact test, or Student t test, as appropriate
Cardiovascular markers, neuroendocrine markers and symptoms in HTx recipients and healthy controls
| HTx recipients | Healthy controls | Adj. | ||
|---|---|---|---|---|
| Cardiovascular markers | ||||
| Systolic blood pressure, supine—mmHg, mean (SD) | 131.5 (14.9) | 125.4 (14.6) |
| 0.082 |
| Diastolic blood pressure, supine—mmHg, mean (SD) | 78.9 (8.4) | 78.1 (9.1) | 0.638 | 0.960 |
| Left ventricular ejection fraction—%, mean (SD) | 58.5 (5.4) | 58.2 (4.6) | 0.799 | 0.164 |
| Neuroendocrine markers | ||||
| Plasma NT-pBNP—ng/l, median (IQR) | 901 (926) | 51 (66) |
|
|
| Plasma norepinephrine—pmol/l, median (IQR) | 2072 (1844) | 2041 (1139) | 0.697 | 0.375 |
| Urine norepinephrine:creatinine ratio—nmol/mmol, median (IQR) | 9.0 (7.2) | 12.2 (8.3) |
| 0.178 |
| Plasma epinephrine—pmol/l, median (IQR) | 577 (405) | 563 (373) | 0.563 | 0.577 |
| Urine epinephrine:creatinine ratio—nmol/mmol, median (IQR) | 1.5 (1.2) | 1.7 (1.2) | 0.175 | 0.665 |
| Symptoms | ||||
| Orthostatic symptoms—total score, mean (SD) | 0.7 (0.8) | 0.5 (0.8) | 0.206 | n.a.c |
| Pale and cold hands—score, mean (SD) | 1.6 (1.2) | 1.3 (0.9) |
| n.a.c |
Numbers in bold indicate a p value < 0.05
NT-pBNP N-terminal pro-brain natriuretic peptide, SD standard deviation, IQR interquartile range, HTx heart transplant
aBased upon Chi square test, Fisher’s exact test, Student t test, or Mann–Whitney U test, as appropriate
bAdjusted according to group differences in activity levels (steps/day)
cNot applicable, as the statistical prerequisites for linear regression-based adjustment were not met
Cardiovascular variables at supine rest, and responses to head-up tilt and handgrip in HTx recipients and healthy controls. Mean (95% confidence interval)
| Supine rest | Response to tilt, 60° head up | Response to handgrip, 30% max force | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HTx recipients | Healthy controls | Adj. | HTx recipients | Healthy controls | Adj. | HTx recipients | Healthy controls | Adj. | ||||
| Heart rate—beats/min | 81.6 (78.7 to 84.6) | 56.0 (53.7 to 58.3) |
|
| 1.9 (0.7 to 3.1) | 14.6 (12.2 to 16.9) |
|
| − 0.3 (− 0.5 to − 0.1) | 5.4 (3.9 to 7.0) |
|
|
| Systolic blood pressure—mmHg | 117.9 (113.9 to 121.9) | 109.0 (105.1 to 112.9) |
|
| 5.8 (1.3 to 10.3) | 11.2 (8.1 to 14.3) |
| 0.117 | 15.1 (12.3 to 18.0) | 17.0 (14.8 to 19.2) | 0.307 | 0.144 |
| Mean arterial blood pressure—mmHg | 90.2 (87.2 to 93.2) | 83.2 (80.1 to 86.3) |
|
| 7.6 (3.7 to 11.4) | 14.6 (11.9 to 17.3) |
|
| 13.5 (10.9 to 16.2) | 16.1 (14.0 to 18.2) | 0.133 | 0.063 |
| Diastolic blood pressure—mmHg | 78.9 (76.0 to 81.7) | 72.4 (69.4 to 75.3) |
|
| 8.4 (5.0 to 11.9) | 15.5 (12.7 to 18.2) |
|
| 11.8 (9.1 to 14.5) | 14.8 (12.6 to 17.0) | 0.085 |
|
| Stroke index—ml/m2 | 29.5 (27.8 to 31.1) | 42.4 (40.0 to 44.7) |
|
| − 0.8 (− 1.9 to 0.4) | − 10.2 (− 12.3 to − 8.0) |
|
| 0.3 (− 0.1 to 0.8) | − 1.7 (− 2.7 to − 0.8) |
|
|
| Cardiac index—l/min/m2 | 2.4 (2.3 to 2.5) | 2.4 (2.2 to 2.5) | 0.906 | 0.314 | 0.01 (− 0.09 to 0.10) | − 0.13 (− 0.28 to 0.02) | 0.126 | 0.363 | 0.01 (− 0.02 to 0.05) | 0.10 (0.03 to 0.17) |
| 0.119 |
| Total peripheral resistance index—mmHg/l/min/m2 | 10.8 (9.9 to 11.6) | 9.2 (8.5 to 9.9) |
|
| 0.9 (0.3 to 1.5) | 1.8 (1.2 to 2.5) |
| 0.199 | 1.5 (1.2 to 1.8) | 1.3 (1.0 to 1.7) | 0.536 | 0.748 |
| End diastolic volume index—ml/m2 | 51.5 (49.0 to 54.0) | 68.6 (65.0 to 72.1) |
|
| 1.0 (− 1.2 to 3.1) | − 11.2 (− 14.6 to − 7.9) |
|
| 0.1 (− 0.5 to 0.7) | − 2.5 (− 3.9 to − 1.1) |
| 0.079 |
Numbers in bold indicate a p value < 0.05
HTx heart transplant
aBased upon Student t test. A Bonferroni-correction due to multiple statistical tests suggests a level of significance of 0.05/26 = 0.002
bAdjusted according to group differences in activity levels (steps/day)
Correlations (Pearson’s r) between cardiovascular variables of interest and possible confounding factors within the HTx recipient group
| Supine: mean arterial blood pressure, mmHg | Supine: total peripheral resistance index, mmHg/l/min/m2 | Tilt response: mean arterial blood pressure, mmHg | Tilt response: total peripheral resistance index, mmHg/l/min/m2 | Handgrip response: cardiac index, l/min/m2 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
| ||||||
| Glomerular filtration rate, estimated, ml/min/1.73 m2 | 0.19 | 0.185 | 0.06 | 0.710 | 0.10 | 0.512 | 0.11 | 0.483 | − 0.16 | 0.303 |
| HbA1c, % | 0.00 | 0.991 | − 0.25 | 0.081 | 0.05 | 0.740 | 0.07 | 0.652 | − 0.25 | 0.100 |
| Steps per day, number | 0.11 | 0.534 | 0.10 | 0.549 | − 0.15 | 0.409 | − 0.05 | 0.760 | − 0.02 | 0.910 |
| NT-pBNP, ng/l | 0.04 | 0.793 | − 0.02 | 0.877 | − 0.22 | 0.147 | − 0.12 | 0.428 | 0.07 | 0.644 |
| Urine Norepinephrine:creatinine ratio, nmol/mmol | − 0.26 | 0.080 | 0.08 | 0.596 |
|
| 0.20 | 0.183 | − 0.11 | 0.488 |
| Cyclosporine dosagea, mg/day | 0.20 | 0.255 | − 0.05 | 0.787 | 0.05 | 0.767 | 0.10 | 0.557 | 0.10 | 0.604 |
| Tacrolimus dosageb, mg/day | − 0.09 | 0.777 | − 0.18 | 0.573 | 0.47 | 0.145 | 0.55 | 0.081 | 0.14 | 0.659 |
| Prednisolone dosagec, mg/day | 0.17 | 0.243 | − |
| − 0.20 | 0.193 | − 0.12 | 0.443 | − 0.07 | 0.652 |
| Controlled for weight (partial corr.) | − 0.03 | 0.842 | ||||||||
| Metoprolol dosaged, mg/day | 0.05 | 0.870 | 0.38 | 0.196 | − 0.24 | 0.457 | − 0.28 | 0.382 | − 0.30 | 0.343 |
| Valganciclovir dosagee, mg/day | 0.13 | 0.558 | 0.01 | 0.955 | − 0.12 | 0.602 | − 0.15 | 0.508 | 0.12 | 0.613 |
Numbers in bold indicate a p value < 0.05
NT-pBNP N-terminal pro-brain natriuretic peptide, HTx heart transplant
aUsed by a total of 36 HTx recipients
bUsed by a total of 13 HTx recipients
cUsed by a total of 50 HTx recipients
dUsed by a total of 14 HTx recipients
eUsed by a total of 22 HTx recipients
Cardiovascular variables of interest in subgroups of HTx recipients according to medication usage. Mean (95% confidence intervals)
| Diureticsa | Calcium blockerb | Betablockerc | All HTx recipientsd | All healthy controlsd | ||||
|---|---|---|---|---|---|---|---|---|
| Yes ( | No ( | Yes ( | No ( | Yes ( | No ( | |||
| Supine: mean arterial blood pressure, mmHg | 88.9 (85.6 to 92.3) | 95.7 (89.3 to 102.1) | 94.1 (89.5 to 98.6) | 88.9 (85.2 to 92.6) | 92.1 (86.6 to 97.6) | 89.4 (85.7 to 93.1) | 90.2 (87.2 to 93.2) | 83.2 (80.1 to 86.3) |
| Supine: total peripheral resistance index, mmHg/l/min/m2 | 10.7 (9.7 to 11.7) | 11.1 (10.0 to 12.3) | 10.3 (8.9 to 11.7) | 10.9 (9.9 to 12.0) | 11.1 (9.0 to 13.3) | 10.6 (9.7 to 11.5) | 10.8 (9.9 to 11.6) | 9.2 (8.5 to 9.9) |
| Tilt response: mean arterial blood pressure, mmHg | 6.6 (2.6 to 10.6) | 12.1 (− 1.3 to 25.4) | 3.1 (− 3.0 to 9.1) | 8.8 (4.2 to 13.5) | 7.3 (0.5 to 14.1) | 7.7 (2.8 to 12.5) | 7.6 (3.7 to 11.4) | 14.6 (11.9 to 17.3) |
| Tilt response: total peripheral resistance index, mmHg/l/min/m2 | 0.7 (0.02 to 1.3) | 1.9 (− 0.01 to 3.9) | 1.2 (− 0.3 to 2.6) | 0.8 (0.1 to 1.5) | 1.0 (− 0.1 to 2.0) | 0.9 (0.1 to 1.7) | 0.9 (0.3 to 1.5) | 1.8 (1.2 to 2.5) |
| Handgrip response: cardiac index, l/min/m2 | 0.01 (− 0.03 to 0.05) | 0.04 (− 0.08 to 0.17) | 0.06 (− 0.03 to 0.16) | − 0.003 (− 0.04 to 0.4) | − 0.01 (− 0.08 to 0.06) | 0.02 (− 0.02 to 0.07) | 0.01 (− 0.02 to 0.05) | 0.10 (0.03 to 0.17) |
Numbers in bold indicate a p value < 0.05
HTx heart transplant
aIncludes bumetanide (n = 37), furosemide (n = 2) and thiazide (n = 5)
bIncludes nifedipine (n = 10) and amlodipine (n = 3)
cIncludes metoprolol (n = 14) and carvedilol (n = 1)
dShown for clarity